The Anders Björkman Malaria Project - Malaria treatment and control

Denna sida på svenska

Improving Diagnosis, Treatment and Control/Elimination of Plasmodium falciparum Malaria

Our research has historically addressed chal­lenges of improving diagnosis, treatment and control of Plasmodium falciparum malaria. A major aim has continuously been to apply new biomedical technologies to respond to parasito­logical, clinical and epidemiological research questions. That implies studies on  diagnostic technologies (e g 1 ) and malaria therapies and studies on the possible evolution and selection of different genetic parasite alterations potentially associated to re­sistance to detection, diagnosis and/or treatment of P. fal­ciparum. A main overall aim is to address the research question “is it possible to eliminate malaria from a high endemic region, typical of sub Saharan Africa?”.Our main research site is Zanzibar where our project has been uniquely successful reaching “pre-elimination”. We are now exploring new interventions to possibly and further uniquely reach elimination of the locally residual transmission.

Group members

Berit SchmidtAssociated

08-524 868 05

Rory BarnesAssociated

Anders BjörkmanProfessor, senior

08-524 868 29

Ulrika MorrisPostdoc


The main present malaria projects in the malaria research unit at Karolinska Institutet include new strategies for malaria elimination and anti-malarial treatments, evolution of drug resistance, and new tools and strategies for malaria diagnosis. Follow the links to find out more about each project.

New strategies for malaria control - aiming at elimination in Zanzibar

Zanzibar was first in Sub-Saharan Africa to implement new modern partly novel malaria control/elimination methods on a wide scale, including tools such as rapid malaria diagnostic tests, artemisinin-based combination therapies, insecticide-treated bed nets and indoor residual spraying. Our Zanzibar project has therefore developed into a model pilot project for modern control/elimination interventions in endemic malaria situations commonly found in Sub-Saharan Africa.

Our results have shown a unique massive decrease in malaria transmission and public health burden (reduced morbidity and mortality), creating hope for the potential elimination of malaria on the isles of Zanzibar and the African continent. Our present aim is to provide historical evidence and proof of concept for possible malaria elimination from a high endemic area.

Specific studies focus on new targeted elimination strategies, are now being undertaken to develop novel methods for malaria incidence surveillance and, drug resistance monitoring, and understanding as well as ensuring the sustainability of intervention usage and community uptake. The implications of successful malaria elimination control on the socio-economic development of Zanzibar will also be studied.


Modern artemisinin-based combination drugs against malaria - malaria drugs and evolution of resistance

The global strategy for malaria control/elimination relies on sustained high efficacy of artemisinin-based combination therapies (ACT) as an anti-malarial treatment. The high efficacy of ACTs relies on the fast acting artemisinin component together with the long acting partner drugs. The emergence of resistance to ACTs poses one of the largest challenges in malaria control and elimination.

We employ in vivo and in vitro methods to study the selection of resistant parasite populations following drug exposures. Genetic markers of malaria parasite tolerance and resistance to antimalarial drugs are a useful tool for the surveillance of antimalarial drug resistance. We monitor molecular markers to track the spread of resistance alleles in parasite populations over time. Specific attention is given to the artemisinin family of compounds as well as their partner drugs included in the recommended combination therapies.


New tools and strategies for malaria diagnosis

In the era of decreasing malaria incidence there are needs for more sensitive and effective diagnostic tools. Rapid diagnostic tests (RDTs) is an efficient diagnostic tool for malaria diagnosis in field health facilities, however in low endemic/ pre-elimination areas where a majority of parasite carriers are asymptomatic, the parasite densities are often too low to be detected by RDTs. Molecular technologies like Loop mediated Isothermal Amplification (LAMP) and PCRs are assessed as future tools for diagnosis and surveillance purposes and have been evaluated in several field studies. One of our studies have also focused on the aetiology of non-malarial, microbial manifestations of childhood fever and the efficiency of Integrated Management of Childhood Illness (IMCI) algorithms for optimal management of fever patients.


The Anders Björkman Malaria Group has several collaborations in many parts of the world, the most extensive are:

  • Zanzibar Malaria Control Program, Zanzibar Ministry of Health and Social Welfare, Tanzania
  • Muhimbili University for Health and Allied Sciences, Dar es Salaam, Tanzania
  • Malaria Research and Training Center, University of Bamako, Mali
  • Univesidad Nacional Autonoma de Honduras (UNAH), Tegucigalpa, Honduras
  • The Bandim Health Project, Guinea-Bissau

Malaria facts

Malaria is curable
There are approx 250 million cases of malaria each year
Malaria causes approx 1 million deaths each year
3,3 billion people live in areas of malaria transmission
Malaria costs are estimated to be 12 billion USD per year in Africa alone

Risk Groups

Children under the age of five and pregnant women are most at risk of severe malaria. People living in highly endemic areas develop partial resistance to malaria over time. Children under the age of five, who have not yet had time to develop partial immunity, account for 85% of all deaths from malaria. Pregnant women are also more susceptible due to parasite invasion of the placenta.


The symptoms of malaria are fever, headache, muscle/joint pain and fatigue. If the disease is not cured it will lead to severe malaria, which if left untreated may be lethal.

The malaria parasite

The malaria parasite has a complicated lifecycle with important stages in both mosquitoes and humans.

Malaria is caused by a unicellular parasite of the genus Plasmodium, and is transmitted by the female Anopheles mosquito that bites primarily from dusk to dawn.

In brief, parasites are transmitted to humans in the saliva of the mosquito when the mosquito takes a blood meal. First the parasites invade liver cells and thereafter red blood cells, where the parasites multiply million-fold.

These red blood cells eventually burst releasing the parasites into the blood stream for re-invasion of new red blood cells. This occurs at 46 or 72 hour intervals (depending on the parasite species) resulting in the symptoms of recurrent fever peaks typical of malaria.


Malaria cure

There is a cure for malaria, thanks to efficient antimalarials such as the new artemisinin-based combination therapies.

However, accurate diagnosis and prevention of transmission are equally important in modern malaria control. Methods of prevention include sleeping under insecticide impregnated mosquito nets and indoor spraying with insecticides.

Chemoprophylaxis may also be used by visitors to malaria endemic areas.

More info

For more information about malaria, please visit the WHO malaria website.

WHO - 10 facts on malaria



Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, et al
PLoS Med. 2018 Jun;15(6):e1002579

Pathogen Clearance and New Respiratory Tract Infections Among Febrile Children in Zanzibar Investigated With Multitargeting Real-Time Polymerase Chain Reaction on Paired Nasopharyngeal Swab Samples.
Elfving K, Shakely D, Andersson M, Baltzell K, Msellem M, Björkman A, et al
Pediatr. Infect. Dis. J. 2018 Jul;37(7):643-648






























Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5.
Tanabe K, Arisue N, Palacpac N, Yagi M, Tougan T, Honma H, et al
Vaccine 2012 Feb;30(9):1583-93


Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands.
Cavaco I, Piedade R, Msellem M, Bjorkman A, Gil J
Trop. Med. Int. Health 2012 Jul;17(7):854-7

Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania.
Färnert A, Ursing J, Tolfvenstam T, Rono J, Karlsson L, Sparrelid E, et al
Malar. J. 2012 May;11():176


Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa.
Zwang J, Dorsey G, Djimdé A, Karema C, Mårtensson A, Ndiaye J, et al
Malar. J. 2012 Aug;11():260


Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar.
Fröberg G, Jörnhagen L, Morris U, Shakely D, Msellem M, Gil J, et al
Malar. J. 2012 Sep;11():321

Quinine treatment selects the pfnhe-1 ms4760-1 polymorphism in Malian patients with Falciparum malaria.
Kone A, Mu J, Maiga H, Beavogui A, Yattara O, Sagara I, et al
J. Infect. Dis. 2013 Feb;207(3):520-7

Genetic diversity of Plasmodium vivax and Plasmodium falciparum in Honduras.
Lopez A, Ortiz A, Coello J, Sosa-Ochoa W, Torres R, Banegas E, et al
Malar. J. 2012 Nov;11():391

CYP2C8 status of patients with malaria influences selection of Plasmodium falciparum pfmdr1 alleles after amodiaquine-artesunate treatment.
Cavaco I, Mårtensson A, Fröberg G, Msellem M, Björkman A, Gil J
J. Infect. Dis. 2013 Feb;207(4):687-8

Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.
Fröberg G, Ferreira P, Mårtensson A, Ali A, Björkman A, Gil J
Antimicrob. Agents Chemother. 2013 Feb;57(2):887-92

Prevalence of PCR detectable malaria infection among febrile patients with a negative Plasmodium falciparum specific rapid diagnostic test in Zanzibar.
Baltzell K, Shakely D, Hsiang M, Kemere J, Ali A, Björkman A, et al
Am. J. Trop. Med. Hyg. 2013 Feb;88(2):289-91



Completed Dissertations

Below is a list of completed dissertations


Maja Malmberg

The role of molecular markers in emerging artemether-lumefantrine resistant Plasmodium falciparum


Maria Isabel Mendes Veiga

Plasmodium falciparum drug transporter genes in emerging malaria multidrug resistance


Pedro Ferreira

Molecular basis for the mechanism of action and resistance to artemisinin combination therapy in Plasmodium falciparum

Billy Ephraim Ngasala

Improved malaria case management in under-fives in the era of Artemisinin-based combination therapy in Tanzania

Gabrielle Holmgren

Plasmodium falciparum resistance to amodiaquine in monotherapy and in combination therapy with artesunate


Johan Ursing

Plasmodium falciparum response to chloroquine and artemisinin based combination therapy (ACT) in Guinea-Bissau

Sabina Dahlström

Role of PfATP6 and pfMRP1 in Plasmodium falciparum resistance to antimalarial drugs

Christin Sisowath

The molecular basis of Plasmodium falciparum resistance to the antimalarial lumefantrine


Andreas Mårtensson

PCR adjusted cure rates in clinical trials of antimalarial drugs in Africa : Influence of extended follow-up and consecutive day


Seema Gupta

Experimental Pharmacodynamic and Kinetic Studies Related to New Combination Therapies against Falciparum Malaria


Poul Erik Kofoed

Treatment of uncomplicated malaria in Guinea-Bissau


Sandor Bereczky

Genetic diversity of Plasmodium falciparum infections : Influence on protective malaria immunity

Elsa Tynell

Prevention of transfusion transmitted infections : Donor screening and characteristics of recipient populations


Mita Mainu

Atovaquone/proguanil in malaria



Irina Jovel

Spread and distribution of drug resistance and compensatory mutations in Plasmodium falciparum


Mwinyi I. Msellem

Efficacy of artemisinin based combination therapy and effectiveness of rapid diagnostic test for management of patients with Plasmodium falciparum malaria in Zanzibar


Below are a few malaria related links

Information on

Rapid Diagnostic Tests (RDT)

Postal and visiting adress

Malaria Research
Department of Microbiology, Tumor and Cell Biology
Nobels väg 16
SE-17177 Solna